Melanotan powder (Afamelanotide, NDP-α-MSH; CAS 75921-69-6) is a synthetic analog of α-MSH designed for research on melanogenesis and MC1R signaling. The peptide features N-terminal acetylation and C-terminal amidation, with key substitutions of norleucine (Nle) and D-phenylalanine that enhance stability, making it well-suited for in vitro experiments and pigment-pathway studies in cellular or animal models.
The product is produced by solid-phase peptide synthesis (SPPS) and offered either as raw material or as customizable lyophilized vials. Upon request, we provide additional testing services including purity, peptide content, endotoxin, and residual solvents. As a China-based melanotan manufacturer, Medibridge Biotech supports bulk orders with wholesale pricing, flexible vial customization, and ready-to-ship inventory.
If you need an update on our latest promotions, or wish to source Made in China raw materials directly from our factory, please contact us for details..
COA
|
|
||
|
Product Name |
CAS Number |
Batch Number |
|
Melanotan |
75921-69-6 |
MB2509101102 |
|
Manufacturer Date |
Analysis Date |
Expiry Date |
|
2025-09-10 |
2025-09-11 |
2027-09-09 |
|
Sample Qty Base |
Packing |
Test Method |
|
50.42 KGS |
100GS/ BOTTLE |
HPLC |
|
Item |
Standard |
Results |
|
Purity |
≥98% |
99.47% |
|
Peptide Assay |
≥80% |
89.80% |
|
Mass Spectrum |
1646.85 |
1646.85 |
|
Solubility |
Soluble in water |
Complies |
|
Clarity and color of solution |
Clear and colorless |
Complies |
|
salt |
<5.0% |
1.79% |
|
Water |
≤7.0% |
2.03% |
|
Residual Solvent: Methanol |
||
|
≤0.3% |
0.0055% |
|
|
Acetonitrile |
≤0.041% |
0.031% |
|
Methylene Chloride |
≤0.06% |
0.029% |
|
N,N-Dimethylformamide |
≤0.088% |
N.D. |
|
Triethylamine |
≤0.032% |
N.D. |
|
Tert-butyl methyl ether |
≤0.5% |
0.216% |
|
Endotoxin |
≤0.5 EU/mg |
Complies |
|
Microbial Limit |
Total aerobic bacteria <100 CFU/g Total yeast & mold <50 CFU/g |
<50 CFU/g <10 CFU/g |
|
Storage |
Keep in dark and cool dry place (-20 to 8°C) |
|
|
Conclusion |
The batch conforms to the IN-HOUSE standard |
|
|
|
||
Products Description
|
Form |
Sample Order |
Specification |
|
Raw powder |
1 g |
Purity is NLT 99% |
|
Vials |
10 vials |
3ml/5ml/7ml/15ml vials etc. |
Literature Snapshot
Studies on Afamelanotide (Melanotan-1) highlights selective MC1R agonism with cAMP–MITF activation, up-regulating TYR/TRP1/DCT and biasing toward eumelanin. Across models, pigmentation gains track with signals of photoprotection, including fewer UV-induced DNA-damage markers. Clinically, an implant formulation has been used in EPP to extend light tolerance and improve patient-reported outcomes; tolerability is mainly dermatologic/GI and manageable with dosing. Current research centers on mechanism, photobiology, oxidative-stress crosstalk, and repigmentation paradigms.
Scientific Visualization
What dose Melanotan powder do?
Melanotan-1 acts like a "start signal" on melanocytes: it engages MC1R, nudging cells to build and deliver melanin-tiny "umbrellas" that deepen and even skin tone while sharing the load under sunlight. With MT-1, pigmentation can develop with lower UV and speeds up in exposed areas. In EPP, an implant increased pain-free light time and quality of life, likely via added melanin plus antioxidant, DNA-damage–response, and anti-inflammatory effects.
PK circadian rhythm
Afamelanotide, an MC1R agonist, typically shows a rise-then-fall exposure profile in bench models. After administration, levels climb to an early peak before tapering as distribution and clearance take over. The schematic below sketches a seven-day experiment cycle and contrasts single-dose versus controlled-release designs: the former peaks early and declines toward a trough; the latter builds to a broader plateau before easing down. Exact timings vary with species, matrix (plasma/tissue), dose and vehicle, assay sensitivity, and formulation.
Emerging Research Directions
Vitiligo Repigmentation Investigations
Afamelanotide is now being tested in vitiligo as an add-on to narrow-band UVB. The idea is simple: MT-1 "primes" melanocytes, while NB-UVB provides the activation signal, so repigmentation can start sooner and spread farther than light alone. After small studies suggested faster, broader gains-especially in darker skin tones-a large, multi-region Phase III program began comparing the combo with NB-UVB monotherapy using outcomes like T-VASI. Safety has been manageable in prior work (mainly dermatologic/GI). These trials will show whether a peptide + light approach can deliver more durable, whole-body repigmentation in routine care settings.
Multi-Target Weight-Management Research
In the 2023 CUV156 clinical study released by CLINUVEL, researchers evaluated the impact of afamelanotide on UV-induced DNA damage in XP-C patients. Due to impaired DNA repair mechanisms, individuals with XP are highly vulnerable to skin cancer after sun exposure. This study focused on skin damage assessments and whether afamelanotide could enhance the expression of DNA repair markers.
Findings showed that afamelanotide significantly reduced markers of UV-related DNA damage, such as γ-H2AX and CPD, and increased repair signals in some patients. Over a 10-day treatment period, no serious adverse events were reported, and visible skin damage was notably reduced. These results suggest that afamelanotide may activate MC1R pathways, indirectly supporting DNA repair and cellular protection.
According to experts from the British Association of Dermatologists, afamelanotide offers a model for improving DNA repair and skin resilience in XP-C patients.
FAQ
Q: How do you take Melanotan‑1?
A: Clinically: a single‑use 16 mg biodegradable implant inserted subcutaneously near the iliac crest by trained staff, typically about every 2 months during brighter seasons for EPP.
Do not self‑inject or use online "tanning" products; continue standard sun protection as advised by your clinician.
Q: What is the half‑life of Melanotan‑1?
A: The peptide's plasma half‑life is short (about ~1 hour), but the implant provides sustained release over several days; melanin induction and clinical effects often persist for weeks.
Q: When was Melanotan first used?
A: Concept and synthesis emerged in the 1980s; early human studies appeared in the 1990s. MT‑1 gained regulatory approvals for EPP (EU first, later US).
Q: Why isn't "Melanotan" FDA‑approved for tanning?
A: Because cosmetic tanning lacks an approved risk‑benefit profile and safety/quality data. Only MT‑1 (EPP) and MT‑2 (HSDD) are approved indications; "melanotan" sold for tanning remains unapproved and risky.
Q: What's the difference between Melanotan‑1 and Melanotan‑2?
A: MT‑1 (afamelanotide) primarily targets MC1R in melanocytes to stimulate eumelanin; MT‑2 (bremelanotide) is less selective (MC1/3/4/5), with more central effects.
|
Feature |
MT‑1 (Afamelanotide) |
MT‑2 (Bremelanotide) |
|
Receptor profile |
Mainly MC1R |
MC1/3/4/5 (notably MC4R) |
|
Approved use |
EPP: increase pain‑free light time |
HSDD (premenopausal women) |
|
Dosing form |
16 mg SC implant (by HCP) |
1.75 mg SC injection PRN |
|
Common AEs |
Nausea, fatigue, implant‑site reactions, hyperpigmentation/nevus darkening |
Nausea, flushing, vomiting, transient BP changes, headache |
Created Melanotan?
Synthetic melanocortin analogues were developed in the 1980s by University of Arizona researchers (notably Victor Hruby, Mac Hadley and colleagues), leading to MT‑1 and later MT‑2.
Melanotan powder currently shows strong promise in pigmentation research, photoprotection models, and repigmentation studies (e.g., vitiligo) in laboratory settings. If you are looking for a high-quality peptide manufacturer committed to building a long-term and stable partnership, please contact us at: hi@medibridgeapi.com.
Hot Tags: melanotan powder, China melanotan powder manufacturers, suppliers, factory, Cagrilintide Powder, Ipamorelin Powder, Melanotan Powder, Mots C Peptide, Semaglutide Raw Powder, Semax Peptide
